Oral tirzepatide dosage: what the question really means for your treatment

Why there is no oral tirzepatide dosage to follow right now

The question comes up often, and it's fair to wonder. GLP-1 and GIP/GLP-1 medicines have changed weight management in a short space of time, and the arrival of oral semaglutide (Wegovy tablets) in June 2026 made headlines. Oral tirzepatide is a separate molecule and a separate project, Eli Lilly has been researching it, and early clinical data exist, but as of summer 2026 no oral tirzepatide formulation carries a UK marketing authorisation for weight management or any other indication. There is no licensed oral tirzepatide dosage chart to share because there is no licensed product.

That matters practically. Without UK authorisation, no UK pharmacy can dispense it lawfully as a prescription medicine. If you see something sold online or described as oral tirzepatide, that is not an authorised UK product. The MHRA's Yellow Card service is the right place to report anything suspicious.

The practical question, then, is usually one of two things: what does Mounjaro's injection schedule actually look like, or is there an oral alternative worth knowing about? Both are answerable.

How Mounjaro's injection dosage is structured, and why the prescriber decides

Mounjaro is a dual GIP and GLP-1 receptor agonist, which makes it the only medicine of its kind licensed in the UK for weight management. It comes in six strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg) each delivered by a pre-filled KwikPen once a week. The full tirzepatide dosage schedule starts at 2.5 mg. That first pen's job is to let your system adjust: it is a tolerability step, not the dose doing the clinical heavy lifting.

From there, a prescriber titrates upward roughly every four weeks, based on how well you are tolerating the current dose and whether the treatment is producing the expected benefit. The 15 mg level is the maximum; not everyone needs to reach it. In the SURMOUNT-1 clinical trial, participants on the highest dose saw an average body-weight reduction of around 20–21% over 72 weeks, a result referenced in NICE's technology appraisal TA1026, published in December 2024.

What this means in practice is that there is no fixed oral tirzepatide dosage chart to copy, and even the injection schedule is not a self-service plan. Timing, pace of titration, and the right ceiling dose are clinical decisions shaped by your full health picture. A prescriber who has reviewed your consultation answers is the person who sets that course. You can read more about specific steps in the schedule (for instance what the 5 mg stage involves or how patients typically respond at 10 mg, including what the 10 mg tirzepatide dosage guidance covers in more detail) but apply them to yourself only after talking to your prescriber.

The oral option that does exist: Wegovy tablets and how their dosage compares

If the appeal of an oral GLP-1 medicine is real for you (no injections, no refrigeration, fits neatly into a morning routine) the Wegovy tablet is the licensed route available right now. It uses semaglutide, a GLP-1 receptor agonist (single-pathway, compared with tirzepatide's dual action), formulated with an absorption enhancer so it can be taken by mouth.

The tablet schedule runs from 1.5 mg once daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. It is taken first thing on an empty stomach with a small glass of water (before the kettle goes on, before coffee, before anything else) and you wait at least 30 minutes before eating or drinking. No fridge needed, which makes travel simpler.

In the OASIS 4 phase 3 trial, participants who stayed fully adherent to treatment saw an average weight loss of around 17% over 64 weeks; the overall trial average, regardless of adherence, was approximately 13.6%. These are semaglutide figures, not tirzepatide figures. For context on how they compare, our Mounjaro pricing and treatment page sets out the options side by side. Both medicines are prescription-only, and a prescriber assesses which is clinically appropriate for you based on your individual circumstances.

What the decision actually comes down to

If you are weighing up injection versus tablet, or trying to understand which doses might apply to your situation, the relevant starting point is a clinical consultation. A prescriber reviews your BMI, any existing health conditions, current medicines (the Mounjaro injection, for example, can affect oral contraceptive absorption during the first four weeks of treatment and after each dose increase, so a prescriber needs to know what else you take), and your own preferences.

At nume, sorry, at our pharmacy, a named GPhC-registered prescriber reads your consultation the same day. There is no algorithm making that call. If you want to know more about how the clinical team approaches these decisions, our lead prescriber's profile is there to read. The FAQs page also covers common questions about the process.

The short version: oral tirzepatide dosage is not a UK clinical reality yet. Injectable Mounjaro is, and so is the Wegovy tablet. Which one suits you (and at what dose) is exactly what a consultation is for. Start your free consultation and a prescriber will work through it with you.